MarginsXMarginsX
Home › Markets › Health Care › JNJ

Johnson & Johnson (JNJ)

JNJ trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$282.55
-1.12% on the day
Market cap
$680.2B
Mega cap
Revenue · 2025
$94.2B
+6.0% on 2024
Net income · 2025
$26.8B
28.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-28, https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/0000200406-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-28.

Profile

FieldValue
TickerJNJ on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000200406
SEC industry codePharmaceutical Preparations
Incorporated inNJ

Financials · 2025

LineValue
Revenue$94.2B
Net income$26.8B
Operating incomeNot in SEC XBRL data
Net margin28.5%
Operating marginOperating income not reported
Revenue growth+6.0%
Cash$19.7B
Total assets$199.2B
P/E (computed)25.4×
P/S (computed)7.2×

Warning signs

Cash runway
Cash-flow positive
$16.9B cash at September 27, 2026
Share count, 1 year
-0.1%
2025-10-17 to 2026-10-15 · 0.0% over 3 years
Going-concern doubt
No
10-Q filed October 21, 2026
Insider net buying, 12 months
-$154.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-21
Cash and burn$16.9B cash; operating cash flow $6.5B a quarter.Report 2026-09-27
Shares outstanding2,407,310,266 (2026-10-15); 2,409,295,102 a year earlier; 2,407,278,620 three years earlier.Cover page 2026-10-15
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-11
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey, United StatesPCAOB Form AP 2026-02-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $258K, sold $154.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-27
$25.4B$210.0M$7.7B$16.9B$44.7B$99.3B10-Q 2026-10-21
Q2 2026
2026-06-28
$25.3B$5.5B$8.6B$20.4B$49.0B$97.9B10-Q 2026-07-23
Q1 2026
2026-03-29
$24.1B$5.2B$2.5B$21.7B$55.0B$96.4B10-Q 2026-04-22
Q4 2025
2025-12-28
$24.6B$5.1B$7.3B$19.7B$49.9B$94.2B10-K 2026-02-11
Q3 2025
2025-09-28
$24.0B$5.2B$9.2B$18.2B$45.8B$92.1B10-Q 2026-10-21
Q2 2025
2025-06-29
$23.7B$5.5B$3.9B$18.6B$50.8B$90.6B10-Q 2026-07-23
Q1 2025
2025-03-30
$21.9B$11.0B$4.2B$38.5B$52.3B$89.3B10-Q 2026-04-22
Q4 2024
2024-12-29
$22.5B$3.4B$7.0B$24.1B$38.4B$88.8B10-K 2026-02-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-02-11
Latest annual report10-K2026-02-11
Latest quarterly / interim10-Q2026-10-21
Latest current report8-K2026-10-13
Latest proxyDEFA14A2026-03-11

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.5%
1 month+14.9%
3 months+9.0%
Year to date+38.1%
1 year+46.4%
From 52-week high0.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ABBVAbbVie Inc.$294.55-0.16%$520.7B
MRKMerck & Company Inc. Common Stock (new)$144.46-2.23%$356.1B
LLYEli Lilly and Company$1431.67-0.82%$1.35T
NVSNovartis AG$160.20-0.19%$305.7B
AZNAstraZeneca PLC$184.02-0.23%$285.4B
ABTAbbott Laboratories$107.45-0.99%$186.1B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
PFEPfizer Inc.$28.86-0.10%$164.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier